Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 23M | 105.8% |
| Gross Profit | 7M | 7.2% |
| Cost of Revenue | 12M | 29.9% |
| Operating expense | 11M | 18.8% |
| Net Income | -4.7M | 28.3% |
| EBITDA | -3.6M | 32.6% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 61M | 7.1% |
| Total Liabilities | 50M | 1.9% |
| Total Equity | 11M | 25.1% |
| Shares Outstanding | 35M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -4.4M | 2.6% |
| Cash from investing | -150,000 | 47.1% |
| Cash from financing | -5,000 | 0% |
EPS
Financial Highlights for Apyx Medical in Q3 '24
Apyx Medical reported a revenue of 23M, which is a 105.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 7M, marking a -7.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 12M, a 29.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 11M, showing a -18.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -4.7M, showing a 28.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -3.6M, showing a 32.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Apyx Medical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
